• Thursday, June 27, 2024 @ 12:00 am

Newron hosted an upbeat investor day, highlighting the blockbuster potential of late-stage schizophrenia drug evenamide. KOLs explained the underlying biology and how evenamide’s unique MOA targets the core abnormalities in schizophrenia, leading to unprecedented efficacy and superior safety in this unresponsive patient population,

Key catalysts include:

  1. Partnering evenamide (before “Study 017”)
  2. H1 2024 results (19 September 2024)
  3. Start “Study 017” trial evenamide in TRS (Q4 2024)

Newron Valuation Report

You may also be interested in